RORC2, A NEW TH17-SPECIFIC THERAPEUTIC TARGET TO TREAT VIRAL INFECTIONS

Abstract

[...]viral reservoir persist in long-lived memory Th17 cells of people living with HIV (PLWH) receiving viral-suppressive antiretroviral therapy (ART) and represent a major barrier against HIV eradication (reviewed in [1, 4]). [...]these RORC2 inhibitors may interfere with RORC2-gouverned transcriptional program that is associated with the expression of multiple HIV permissiveness factors in Th17 cells. [...]given Th17 pathogenicity during SARS-CoV-2 infection, when they promote the massive infiltration of inflammatory neutrophils in the lungs [3], there is a need to test RORC2 inhibitors in animal models.